A.M. Parfitt, MB, BChir
To the Editor: Gallagher and Riggs (1) recently criticized the report by Ott and Chesnut (2) on calcitriol treatment in postmenopausal osteoporosis. They referred to their own placebo-controlled study (3), which found that "3 years of treatment with calcitriol of women with postmenopausal osteoporosis resulted in a highly significant 65% reduction of vertebral fracture rate." They failed to mention that the placebo was given for only 1 year, so that the fracture rates in the second and third years of calcitriol treatment were compared with historical, not with concurrent, controls. In another study (4) cited by Gallagher and
Learn more about subscription options.
Register Now for a free account.
Parfitt A. Calcitriol for Postmenopausal Osteoporosis. Ann Intern Med. 1990;112:147. doi: 10.7326/0003-4819-112-2-147_1
Download citation file:
Published: Ann Intern Med. 1990;112(2):147.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only